Anti-inflammatories or NSAIDs are one of the most prescribed drugs in the world and Lexaria has a new oral delivery method for improved taste, smell and absorption.
Lexaria’s DehydraTECH drug delivery platform is the first method around the world for the delivery of vitamins. For NSAIDs and for the active ingredients in smoking cessation products, to be delivered through common foods like coffee or tea.
The company evolved into its current form in 2014 upon controlling acquisition of the former company where Lexaria’s DehydraTECH™ technology originated.
Since then, Lexaria has quickly emerged as a global leader in enhancing the flavor, bouquet and gastro-intestinal delivery of edible cannabinoid consumer products. While also working to expand the applicability of its technology, within and beyond the cannabinoid sector, through its out-licensing business model for cannabinoids and other bioactive molecules named in its patent portfolio (NSAIDs, nicotine, vitamins and more).
Producing industry-leading research to support its novel delivery method. None of this can happen without the talented and dedicated people who have supported Lexaria’s development and growth.
Lexaria has always maximized its resources by attracting top management and advisors and also leveraging the strongest expert consultant relationships.
Supporters have included industry leaders, research scientists, clinicians, analytical chemists, intellectual property experts, study volunteers, partnering company collaborators and, of course, the original inventors of the earliest iterations of Lexaria’s DehydraTECH™ technology.
For more information on Lexaria Bioscience Corp. (Nasdaq: LEXX) please fill out the form below.